$18.20
-0.00 (-0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AAPG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
52 interventional · 1 expanded access
Held by 1 tracked-famous manager (Point72 Asset Management, L.P.) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of APG-3288 in Relapsed/Refractory Blood CancersNCT07424833Incidence of dose-limiting toxicities (DLTs) at each dose levelNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: APG-3288 | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL) | 180 | Dec 2029 | ≤ 1,230 d | 2026-07-30 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLNCT04260022Maximum Plasma Concentration (Cmax) of HQP1351Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab | Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia | 242 | 2029-12-27 | in 1,226 d | 2025-11-05 |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).NCT06641414Overall Survival（OS）Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Lisaftoclax (APG-2575), Azacitidine Injection · Other: Placebo | Higher-risk Myelodysplastic Syndrome | 490 | Jun 2029 | ≤ 1,046 d | 2025-11-20 |
| Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLNCT04501120Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575), olverembatinib | Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | 682 | Sep 2028 | ≤ 773 d | 2026-04-29 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaNCT06389292Overall Survival（OS）Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: APG-2575(Lisaftoclax ), Azacitidine Injection · Other: Placebo | Acute Myeloid Leukemia | 486 | 2028-05-25 | in 645 d | 2025-11-25 |
| A Study of HQP1351 in Patients With GIST or Other Solid TumorsNCT03594422Safety and toleranceRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: HQP1351 | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 100 | Dec 2027 | ≤ 499 d | 2026-04-09 |
| APG-2449 in Patients With Advanced Solid TumorsNCT03917043Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Recruiting | Drug: APG-2449 | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 165 | Dec 2027 | ≤ 499 d | 2026-07-23 |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.NCT05773586Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: APG-5918, Placebo | Anemia | 105 | 2027-12-31 | in 499 d | 2026-04-15 |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)NCT06051409Minimal Residual Disease Negative CR RateRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Olverembatinib, Investigator's choice of TKI | Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 350 | 2027-12-31 | in 499 d | 2026-04-30 |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456Progress Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | CLL/SLL | 344 | Aug 2027 | ≤ 377 d | 2026-07-28 |
| APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STNCT06687070Treatment-related adverse events per NCI-CTCAE version 5.0.Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: APG -2449, PLD | Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | 90 | May 2027 | ≤ 285 d | 2026-07-21 |
| A Study of Olverembatinib in SDH-deficient GIST.NCT06640361Progression-free survival(PFS) rateOpen-label · Treatment | Phase 3 | Recruiting | Drug: Olverembatinib | GIST | 40 | 2027-03-31 | in 224 d | 2026-07-23 |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Recruiting | Drug: APG2575 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 75 | Dec 2026 | ≤ 134 d | 2026-03-27 |
| Global Trial in APG2575 for Patients With CLL/SLLNCT06104566PFSRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: lisaftoclax +BTK inhibitor, BTK inhibitor | CLL/SLL | 400 | 2026-12-31 | in 134 d | 2026-06-18 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentNCT07282093Maximum observed plasma concentration C(max)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Olverembatinib 20mg | Pharmacokinetic, Olverembatinib | 48 | 2026-06-30 | — | 2025-12-23 |
| APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid TumorsNCT05701306Dose Limiting Toxicity (Phase I)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: APG-115, APG-2575 | Neuroblastoma, Solid Tumor | 100 | 2026-06-01 | — | 2025-02-25 |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLNCT04496349Maximum tolerated dose of APG-115Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: APG-115, APG-2575 | T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | 78 | 2026-05-31 | — | 2025-11-04 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsNCT04785196Dose Limiting Toxicity (Phase I)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: APG-115, Toripalimab | Liposarcoma, Advanced Solid Tumor | 95 | Apr 2026 | — | 2025-02-26 |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.NCT06182969Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: APG-2575 · Other: Placebo | SLE | 40 | Apr 2026 | — | 2025-12-16 |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsNCT04001777Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: APG-1252, Osimertinib Mesylate Tablets | EGFR Positive Non-small Cell Lung Cancer | 80 | Dec 2025 | — | 2025-10-01 |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.NCT04275518Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: APG-115, Azacitidine, Cytarabine | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 102 | 2025-12-31 | — | 2024-10-15 |
| Study of Olverembatinib (HQP1351) in Patients With CP-CMLNCT06423911MMR rate Part ARandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: olverembatinib, Bosutinib | Chronic Myeloid Leukemia, CML, CML, Chronic Phase | 285 | Dec 2025 | — | 2025-06-03 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsNCT03611868Maximum Tolerated DoseOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Phase 1b: APG-115+pembrolizumab | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 230 | 2025-12-30 | — | 2025-08-07 |
| Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLNCT04215809Primary Toxicity Endpoint: dose limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Lisaftoclax | CLL/SLL | 144 | 2025-10-31 | — | 2025-04-10 |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNCT03913949Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: APG-2575 | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 74 | 2024-10-20actual | — | 2026-05-01 |
| Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLNCT04494503Adverse events of APG-2575 single agentNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: APG-2575, Rituximab, Ibrutinib | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 123 | 2024-10-20actual | — | 2025-04-16 |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesNCT03537482Maximum Tolerated Dose (MTD)Open-label · Treatment | Early Phase 1 | Recruiting | Drug: APG-2575 | Hematologic Malignancies | 90 | 2024-09-15 | — | 2024-08-19 |
| APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaNCT05186012Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: APG-1252, Chidamide | NHL, Adult | 51 | Sep 2025 | — | 2024-01-23 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSNCT04358393Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: APG-115, 5-azacitidine | AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS | 69 | 2024-12-30 | — | 2024-02-01 |
| Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsNCT04284488Recommended Phase 2 dose(RP2D) (Applicable for: phase I stage in various solid tumor types).Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Company Strategy | Drug: APG-1387 for Injection, Toripalimab | Advanced Solid Tumor | 40 | 2024-11-30actual | — | 2026-01-08 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098Dose-limiting Toxicity (DLT)Randomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: APG-5918 | Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma | 90 | 2024-09-30 | — | 2022-11-16 |
| APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaNCT04942067Dose limiting toxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: APG-2575+ Pd, APG-2575 + DRd | Multiple Myeloma, Amyloidosis | 108 | 2024-09-01 | — | 2023-10-25 |
| A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerNCT04946864DLTNon-randomized · Open-label · Treatment | Phase 1/2 | Suspendedsponsor's stated reason: Company Decision | Drug: APG-2575, Palbociclib | Breast Cancer, Solid Tumor, Adult | 65 | 2024-08-12actual | — | 2024-08-19 |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseNCT04126681Event free survival (EFS)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: HQP1351, Hydroxyurea or Interferon-based therapy, Homoharringtonine, Imatinib, Dasatinib or Nilotinib | Chronic Myeloid Leukemia, Chronic Phase | 144 | 2024-08-01actual | — | 2025-03-03 |
| A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)NCT04964518DLTOpen-label · Treatment | Phase 1/2 | Unknown status | Drug: APG 2575 ramp up arm | AML, Adult | 24 | 2024-07-30 | — | 2023-10-25 |
| APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaNCT04643405Dose Limiting Toxicities (DLT) of combination therapy (Applicable for: phase Ib stage ).Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Company Strategy | Drug: APG-1387 for Injection, Gemcitabine, Nab paclitaxel | Advanced Pancreatic Cancer | 21 | 2024-06-25actual | — | 2026-01-08 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationNCT03883087Major cytogenetic response (MCyR)Open-label · Treatment | Phase 2 | Unknown status | Drug: HQP1351 | Chronic Myeloid Leukemia, Chronic Phase | 41 | May 2024 | — | 2023-04-03 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationNCT03883100Major hematologic response (MaHR)Open-label · Treatment | Phase 2 | Unknown status | Drug: HQP1351 | Chronic Myeloid Leukemia - Accelerated Phase | 23 | Apr 2024 | — | 2023-04-03 |
| APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaNCT04260217Primary Toxicity Endpoint: dose limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Waldenstrom Macroglobulinemia | 46 | 2024-02-05actual | — | 2025-08-19 |
| APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaNCT04674514Dose Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: APG-2575, Rd | Multiple Myeloma | 48 | Jan 2024 | — | 2023-03-07 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyNCT04354727Dose-limiting toxicity (DLT) rate at each dose levelNon-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: APG-1252, Ruxolitinib | Myelofibrosis | 0 | 2022-12-15 | — | 2022-07-12 |
| The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsNCT05517616Radioactivity concentration of each blood and plasma sampleOpen-label · Treatment | Phase 1 | Completed | Drug: [14C ]APG-2575 | Pharmacokinetics | 6 | 2022-11-01actual | — | 2024-01-23 |
| APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesNCT03386526Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: APG-1387 for Injection | Advanced Solid Tumors or Hematologic Malignancies | 90 | 2022-10-31actual | — | 2023-02-01 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis BNCT04568265Dose-limiting toxicity (DLT) rate at each dose levelRandomized · Open-label · Treatment | Phase 2 | Unknown status | Drug: APG-1387, Entecavir 0.5 mg | Hepatitis B, Chronic Hep B, HBV | 122 | 2022-10-31 | — | 2021-08-26 |
| A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsNCT04893759Maximum tolerated dose (MTD) determinationOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company Strategy | Drug: Pelcitoclax | Neuroendocrine Tumors | 2 | 2022-09-14actual | — | 2025-04-17 |
| APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BNCT03585322Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: APG-1387 for Injection | Chronic Hepatitis B | 49 | 2021-10-15actual | — | 2021-11-08 |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerNCT04210037Primary Toxicity Endpoint: dose-limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APG-1252, Paclitaxel | Small Cell Lung Cancer | 28 | 2021-08-30actual | — | 2022-07-12 |
| APG-1252 in Patients With SCLC or Advanced Solid TumorsNCT03387332Dose limit toxicity (DLT) determinationOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The company adjusts strategy. | Drug: APG-1252 | Small Cell Lung Cancer and Other Solid Tumors | 24 | 2020-11-09actual | — | 2021-08-27 |
| A Study of APG-1252 in Patients With SCLC or Other Solid TumorsNCT03080311Dose limiting toxicity (DLT) determinationOpen-label · Treatment | Phase 1 | Completed | Drug: APG-1252 | Small Cell Lung Cancer, Solid Tumor | 50 | 2020-06-22actual | — | 2022-07-12 |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansNCT04126707Radioactivity concentration of each blood and plasma sampleOpen-label · Treatment | Phase 1 | Completed | Drug: [14C] HQP1351 | Chronic Myeloid Leukemia (CML) | 6 | 2020-01-13actual | — | 2021-09-08 |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaNCT03882281Area under the curve from the time of dosing to infinity [AUC(0-inf)]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: HQP1351 | Chronic Myeloid Leukemia, Chronic Phase | 12 | 2019-11-16actual | — | 2020-01-22 |
| APG-115 in Patients With Advanced Solid Tumors or LymphomasNCT02935907Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: APG-115 | Patients With Advanced Solid Tumor or Lymphoma | 50 | 2019-06-28actual | — | 2022-07-12 |
| Named Patient Program for Olverembatinib (HQP1351)NCT05594758expanded access | — | Available | Drug: Olverembatinib | — | — | — | — | 2024-02-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19